Ethic Inc. Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Ethic Inc. grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 132.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,342 shares of the biopharmaceutical company's stock after purchasing an additional 11,597 shares during the quarter. Ethic Inc.'s holdings in Royalty Pharma were worth $519,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Brooklyn Investment Group boosted its stake in Royalty Pharma by 1,006.9% in the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 876 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 877 shares in the last quarter. Riverview Trust Co grew its holdings in shares of Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,186 shares during the last quarter. Fifth Third Bancorp raised its position in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 997 shares during the period. Finally, Blue Trust Inc. raised its position in Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 376 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Trading Down 4.0%

NASDAQ:RPRX traded down $1.38 during midday trading on Tuesday, reaching $32.87. 4,622,218 shares of the stock traded hands, compared to its average volume of 4,709,108. The stock has a market capitalization of $18.95 billion, a P/E ratio of 22.65, a PEG ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The company has a fifty day moving average of $32.42 and a 200 day moving average of $30.06. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.31.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. The firm had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.68%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is currently 47.57%.

Wall Street Analyst Weigh In

RPRX has been the topic of a number of recent research reports. StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Monday, May 12th. Morgan Stanley assumed coverage on Royalty Pharma in a research note on Friday. They issued an "overweight" rating and a $51.00 target price for the company. Finally, Citigroup restated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of "Buy" and an average price target of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.